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Abstract 
There is increasing evidence demonstrating that adult neural stem cells (NSCs) are a 
cell of origin of glioblastoma. Here we have analysed the interaction between transformed and 
wild-type NSCs isolated from the adult mouse subventricular zone niche. We find that 
transformed NSCs are refractory to quiescence-inducing signals. Unexpectedly, we also 
demonstrate that these cells induce quiescence in surrounding wild-type NSCs in a cell-cell 
contact and Notch signalling-dependent manner. Our findings therefore suggest that oncogenic 
mutations are propagated in the stem cell niche not just through cell-intrinsic advantages, but 
also by outcompeting neighbouring stem cells through repression of their proliferation. 
Introduction 
In the adult mammalian brain, neural stem cells (NSCs) can be primarily found in 
specific neurogenic regions. In rodents these include the sub-granular zone (SGZ) of the 
dentate gyrus (DG) and the subventricular zone (SVZ), which lines the lateral ventricles 
(Doetsch et al. 1999; Sanai et al. 2004; Quinones-Hinojosa et al. 2006). In the SVZ niche NSCs 
coexist in both quiescent and activated states (Quinones-Hinojosa et al. 2006). Tight regulation 
of the switch between these two states is vital to ensure that the pool of NSCs does not 
accumulate DNA damage or become exhausted with time, and therefore understanding how 
this is achieved is of great interest. The feedback mechanisms that exist to regulate the balance 
of stem cell activation and quiescence during normal homeostasis remain poorly understood. 
Adult NSCs are believed to be a cell of origin in certain brain tumours. One possibility is that 
these cells accumulate driver mutations over time that compromise the normal controls on their 
proliferation and migration. These transformed NSCs then escape the niche and acquire further 
mutations resulting in tumour formation. This has been hypothesised to be the case in 
glioblastoma (GBM), the most aggressive form of malignant glioma (Louis et al. 2007; Rispoli 
et al. 2014). In particular, the discovery of a subpopulation of cells within GBM tumours with 
stem cell characteristics, known as glioblastoma stem cells (GSCs), has lent weight to this 
notion. This GSC population shares many common features with adult NSCs, including 
expression of stem and progenitor cell markers, self-renewal capacity, and the ability to 
generate multilineage progeny (Singh et al. 2004; Cheng et al. 2013). Importantly, GSCs are 
also able to generate tumours in mice that recapitulate all the classical features of GBM, even 
when injected in low numbers (Galli et al. 2004; Singh et al. 2004).  
Adult NSCs can be isolated from the SVZ of murine brains and cultured as adherent cultures 
under conditions that promote symmetric self-renewal and prevent differentiation (Conti et al. 
2005; Pollard et al. 2006). Furthermore, by using NSCs engineered with oncogenic drivers, 
these in vitro culture systems can be useful as a model of brain tumour development to 
understand cellular transformation. Here we exploit this system to understand how transformed 
NSCs influence wild-type NSCs.   
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Results and Discussion 
Transformed NSCs are refractory to quiescence-inducing signals. 
To understand how transforming mutations affect the quiescent or activation status of NSCs, 
we compared NSCs derived from wild-type mice (WT-NSCs) to those isolated  from Ink4a/Arf-
/- mice and transduced with a retrovirus expressing the EGFRvIII mutation (IE-NSCs) 
(Bruggeman et al. 2007). This combination of mutations is frequently observed in human GBM 
(Crespo et al. 2015) and induces transformation in NSCs, as indicated by their ability to 
generate tumours in vivo that recapitulate many of the features of human GBM tumours 
(Bruggeman et al. 2007; Marques-Torrejon et al. 2018). We first compared the proliferative 
potential of both these cell types. We observed that, when grown in conditions that promote 
the proliferative NSC state (Pollard et al. 2006), IE-NSCs displayed a small growth advantage 
(Figure 1A and Supplemental Fig. S1A-B). We next investigated if IE-NSCs have a similar 
response to quiescence-inducing signals when compared to WT-NSCs. BMP signalling is 
known to induce a reversible quiescent-like state in hippocampal and embryonic stem cell-
derived NSCs (Mira et al. 2010; Martynoga et al. 2013). For this reason, we treated WT and 
IE-NSCs with 50ng/ml BMP4. We observed that, although this induced similar levels of 
SMAD1/5/8 phosphorylation in both cell types (Supplemental Fig. S1C) and efficiently 
suppressed the proliferation of WT-NSCs, it had little effect on the growth of the transformed 
cells (Supplemental Fig. S1D). This suggests that IE-NSCs cells are refractory to the induction 
of quiescence by BMP signalling activation.  
Transformed NSCs suppress the proliferation of surrounding NSCs. 
The experiments described above allowed us to test the proliferative potential of wild-type and 
transformed cells as isolated cell populations. However, we postulated that in the niche these 
cell types are likely to co-exist. For this reason, we next studied the proliferation patterns of 
both cell types in a 50:50 co-culture and compared these proliferative patterns to the growth of 
cell populations in homotypic (separate) cultures.  
IE-NSCs were GFP-labelled, allowing us to accurately quantify the relative cell proliferation 
rates in co-culture using flow cytometry. Given transformed cells produce autocrine and 
paracrine growth factors, these might support increased WT-NSC expansion. Unexpectedly 
however, we observed that in contrast to the exponential growth observed for both cell types 
in separate culture, in co-culture WT-NSCs showed a significant reduction in the rate of 
proliferation (Figure 1B-E and Supplemental Fig. S1E-F). These results suggest that IE-NSCs 
have an acquired inhibitory effect on the proliferation of WT-NSCs.  
To test the above possibility further, co-cultures were established with varying proportions of 
each cell type, ranging from 10 to 90%, and the total number of cells present in co-culture was 
kept constant. Analysis of the fold change in WT-NSC number, which normalises for variations 
in WT-NSC numbers at initial plating, revealed that the reduction in their proliferation was 
directly proportional to the percentage of transformed NSCs present (Figure 1F), to the extent 
that, when 75% of the cells in co-culture were IE-NSCs, the 25% of WT-NSCs barely increased 
in number during the 6-day experiment. Interestingly, cleaved-Caspase3 expression was also 
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elevated in co-cultured WT-NSCs (Supplemental Fig. S1G). However, this increase was only 
significant from day 5 of co-culture when compared to separate cultures. Given that the 
differences in cell number and BrdU incorporation were apparent from day 3, this suggests that 
apoptosis may be due to the compromised ability of arrested NSCs to survive long-term in pro-
proliferative conditions. Together, these results indicate that IE-NSCs suppress the 
proliferation of activated WT-NSCs. 
Transformed NSCs induce a quiescent-like state in neighbouring wild-type NSCs 
To gain a deeper insight into the mechanism of proliferative arrest of co-cultured WT-NSCs, 
we compared their transcriptional profile to WT-NSCs grown in separate cultures. Cells were 
isolated by FACS after 5 days of co-culture, and RNA-seq was performed. Analysis of 
differential gene expression with Ingenuity Pathway Analysis, which uses functional 
annotations and interactions of genes to identify enriched pathways, revealed that the majority 
of the top canonical pathways enriched in co-cultured WT-NSCs were related to cell cycle 
control and DNA repair (Figure 2A-B), consistent with the observed proliferation arrest 
induced by transformed cells. 
One possible explanation for this cell cycle arrest is differentiation into post-mitotic cell types, 
such as immature neurons. The expression of NSC markers, together with markers for 
intermediate progenitors and differentiated cell types (Zhang and Jiao 2015), was therefore 
explored in our RNA-seq data-set. No broad downregulation of classical NSC markers or any 
upregulation of differentiation markers was observed in co-cultured WT-NSCs compared to 
their separate counterparts (Supplemental Fig. S2A). Interestingly, we did observe an 
upregulation in the expression of the glial markers, Gfap, Glt1 and Glast, which are enriched 
in quiescent NSCs (Codega et al. 2014; Llorens-Bobadilla et al. 2015). These observations 
suggest that WT-NSCs are not differentiating, but instead may be driven into a quiescent 
astrocytic-like state. 
To explore this last possibility, we analysed our RNA-seq data-set for the expression of a 
broader set of quiescent and activated NSC markers. We found that the quiescence-associated 
transcriptional regulators, Sox9, Id2, Id3 and Klf9, which are upregulated in quiescent SVZ 
NSCs (Llorens-Bobadilla et al. 2015; Morizur et al. 2018), were all also upregulated in the co-
cultured WT-NSCs (Figure 2C). We also observed that markers of activated NSCs, Ascl1, 
Egr1, Fos and Sox11 (Andersen et al. 2014; Llorens-Bobadilla et al. 2015; Morizur et al. 2018), 
were downregulated in these cells. When we compared our RNA-seq data-set with a list of 
transcription factors and co-factors that have been found to be differentially expressed between 
activated and quiescent SVZ NSCs (Morizur et al. 2018), we found that of the 14 genes 
enriched in quiescent cells in this study, 10 were upregulated in co-cultured WT-NSCs, and of 
the 61 genes enriched in activated NSCs, 50 were downregulated (Supplemental Fig. S2B). 
Together these findings therefore support the hypothesis that the co-cultured NSCs are 
adopting a quiescent phenotype. 
To test if the quiescent WT-NSCs remain multipotent after co-culture with transformed NSCs, 
we co-cultured both these cell types for 5 days, sorted the WT-NSCs and then re-plated them 
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in differentiation inducing conditions. When this was done, we observed that the co-cultured 
WT-NSCs had a similar ability to differentiate into astrocytes, neural progenitors and neurons 
as separately cultured WT-NSCs did (Figure 2D-E and Supplemental Fig. S2C-D). This 
indicates that the co-cultured quiescent NSCs retain multipotency. 
A key feature of a quiescent phenotype is its reversibility. To test if the proliferation arrest of 
WT-NSCs in co-culture is reversible, we sorted WT and IE-NSCs after 5 days in co-culture 
and re-plated them. In parallel, WT-NSCs that had been cultured separately were mixed with 
transformed cells just before sorting and subsequently re-plated. Importantly, we observed that 
previously co-cultured WT-NSCs displayed a similar proliferation rate to NSCs that had been 
separately cultured throughout, as judged by their growth curves and BrdU incorporation 
(Figure 2F-G). The reversible nature of the proliferation arrest of co-cultured WT-NSCs 
provides further evidence that they are entering a quiescent state rather than becoming 
senescent or terminally differentiated. 
Cell contact is required for the inhibitory effect of transformed cells 
To understand the mechanisms underlying the interaction between WT and transformed NSCs, 
we first analysed the possible involvement of the mTOR signalling pathway. mTOR is a 
metabolic regulator that senses growth factor and nutrient inputs. It is activated in transit 
amplifying progenitor cells and its inhibition induces quiescence in adult NSCs (Paliouras et 
al. 2012). Analysis of the expression of ribosomal protein S6 phosphorylation (p-S6), a read-
out of mTOR activity indicated that mTOR signalling levels were reduced in co-cultured WT-
NSCs, not only relative to these same cells in separate culture, but also to IE-NSCs in co-
culture (Figure 3A). We next tested if constitutive mTOR activation was sufficient to prevent 
these NSCs from entering quiescence in co-culture. For this we mutated Tsc2, an mTOR 
repressor in WT-NSCs, using CRISPR-Cas9 targeting (Supplemental Fig. S3A). However, we 
found that, although this was sufficient to sustain strong mTOR pathway activation, Tsc2-/- 
NSCs still entered a proliferation arrest when co-cultured with IE-NSCs (Supplemental Fig. 
S3B-D). This indicates that mTOR inhibition is not the primary event for the induction of 
quiescent phenotype of co-cultured WT-NSCs. 
Next, we investigated the possibility that cell contact is required to induce the growth arrest of 
WT-NSCs. We first used a transwell assay, where the two cell types are separated by a 
permeable membrane that allows the exchange of signalling factors in the media while 
physically separating the cells. When WT-NSCs were separated from IE-NSCs by the 
transwell, they grew similarly to WT-NSCs in homotypic cultures (Figure 3B). This suggests 
that secreted paracrine factors are not sufficient to induce quiescence. We further tested this 
possibility by using fences, which are metal inserts that divide the well into an inner and outer 
ring. One cell type is plated in the inner ring and the second in the outer ring (Figure 3C) and 
once they are growing adherently, the inserts can be removed leaving behind a small gap 
between the two populations. Using this system, we compared the proliferation rate of WT-
NSCs that were separated from IE-NSCs to their proliferation when separated from other WT-
NSCs or when mixed with IE-NSCs. We found that the rate of BrdU incorporation of the WT-
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NSCs did not decrease when they were not in physical contact with the IE-NSCs (Figure 3C). 
This indicates that cell-cell contact is most likely required for IE-NSCs to inhibit the 
proliferation of WT-NSCs. 
Transformed cells signal via Notch and Rbpj to induce quiescence in wild-type NCSs 
The Notch pathway is a highly conserved signalling pathway requiring cell-cell contact that 
plays a central role in the regulation of embryonic and adult neurogenesis (Ables et al. 2011; 
Urban and Guillemot 2014). To test if Notch signalling is required to trigger quiescence, we 
first explored the expression of Notch signalling pathway components in our RNA-seq data. 
Interestingly, we found that the majority of Notch-related genes were upregulated in WT-NSCs 
compared to IE-NSCs, including many Notch targets and receptors, while the Notch ligands 
appeared to be more highly expressed on IE-NSCs in co-culture (Figure 3D). With the 
exception of Jagged1, this higher expression of Notch ligands in IE-NSCs was not dependent 
on their co-culture with WT-NSCs (Supplemental Fig. S4A), suggesting that cell-cell 
communication was not driving this initial difference in expression. Analysis by qPCR of 
sorted samples also revealed that the expression of the Notch target genes Hes1, Hes5, Hes7, 
Hey1, Hey2 and Nrarp were upregulated in co-cultured WT-NSCs (Figure 3E). This suggests 
that Notch pathway activity is higher in co-cultured WT-NSCs than in IE-NSCs and raises the 
possibility that transformed cells may be signalling to WT-NSCs via this pathway. 
To test the functional significance of this difference in Notch activation, two complementary 
γ-secretase inhibitors were used to block Notch signalling. We observed that both LY411575 
(LY) and crenigacestat reduced Notch target gene expression in NSCs. Importantly, these also 
partially rescued the proliferation arrest of co-cultured WT-NSCs. The growth curves and 
BrdU incorporation rates of co-cultured NSCs treated with the γ-secretase inhibitors were only 
slightly lower than their growth is separate culture (Figure 3F-G and Supplemental Fig. S4B-
F). This suggests that Notch signalling is required for the induction of quiescence in NSCs by 
transformed cells. 
To further test the requirement for Notch signalling we mutated Rbpj, a key effector of this 
pathway, as well as Notch1 and Notch2 by CRISPR/Cas9 targeting (Figure 4A, D and G).  Rbpj-
/-, Notch1-/- or Notch2-/- NSCs were not susceptible to proliferation arrest when co-cultured with 
IE-NSCs and grew at similar growth rates in separate and co-culture (Supplemental Fig. S5A-
D). Similarly, the fold change in cell number and BrdU incorporation rates of co-cultured Rbpj-
/-, Notch1-/- and Notch2-/- NSCs was similar to separate culture and significantly higher than 
that of WT-NSCs co-cultured with IE-NSCs (Figure 4B-C, E-F and H-I). Interestingly, both 
the growth curves and final cell counts of Rbpj-/- NSCs indicated that these cell types even 
outcompeted IE-NSCs in co-culture (Figure 4B and Supplemental Fig. S5B), suggesting that 
disrupting Notch signalling may be sufficient to provide NSCs with a competitive advantage 
against transformed NSCs. The ability of both Notch1 and Notch2 deletion to render the NSCs 
insensitive to proliferation arrest suggests that these receptors both have a role in conveying 
the quiescence-inducing signal to WT NSCs. This is in contrast to recent studies that have 
suggested a non-redundant role for Notch2 in promoting NSC quiescence (Engler et al. 2018). 
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It would also suggest that it is not necessary to completely block Notch signalling to prevent 
growth arrest, reducing the strength of the signal through deletion of a single receptor was 
sufficient.  
To exclude the possibility that Notch signalling is required in transformed NSCs, we mutated 
Rbpj in this cell type (Supplemental Fig. S5E). We observed that IE-NSCs still induced the 
proliferation arrest of WT-NSCs, as shown by the growth curves, final cell numbers and BrdU 
incorporation (Supplemental Fig. S5F-H). Therefore, Notch signalling is not required in 
transformed cells for their growth inhibition of WT-NSCs. 
Finally, to test if cells carrying other mutations that induce transformation can also induce 
quiescence in WT-NSCs we analysed Pten-/-; p53-/- NSCs, that when mutated in mice induce a 
glioblastoma-like phenotype (Zheng et al. 2008; Jacques et al. 2010). Mutant NSCs were 
generated by CRISPR/Cas9 targeting and cultured separately or co-cultured with WT-NSCs. 
Indeed, Pten-/-; p53-/- NSCs were capable of inducing a growth arrest in WT-NSCs 
(Supplemental Fig. S6). The ability to induce quiescence in neighbouring cells is therefore not 
dependent on the specific IENS model, but may be a common feature of several different types 
of transformed NSCs. 
Altogether, these data, demonstrate that transformed cells activate Notch signalling in adjacent 
wild-type activated NSCs and triggers transition to quiescence. This observation may have 
implications for understanding of gliomagenesis. In humans, it has been suggested that GBMs 
can arise from the adult SVZ cells and accumulate low-level truncal driver mutations (Lee et 
al. 2018). This niche has also been suggested to harbour malignant cells away from the tumour 
mass, which are more resistant to chemotherapy and may therefore act as a reservoir for 
recurrence (Piccirillo et al. 2015). Furthermore, the SVZ has  been shown to be a permissive 
region for GBM growth, as tumours in contact with this region are associated with decreased 
patient survival and increased recurrence (Khalifa et al. 2017; Mistry et al. 2017).  
Our studies using SVZ-derived wild-type and transformed NSCs demonstrate that transformed 
cells provide a negative feedback via Notch signalling to surrounding normal NSCs, which 
cause them to exit their activated state and re-enter quiescence. By this mechanism, oncogenic 
NSCs outcompete normal NSCs and ensure their preferential self-renewal and differentiation, 
therefore increasing both their cell number and their likelihood of giving rise to progenitor cells 
and exiting the niche. This competitive advantage may be an important early step in the 
development of glioma and GBM. Confirming and tracking quiescent NSCs in vivo and 
establishing how this competition mechanism operates in the complex milieu of the SVZ niche 
are important future directions to understand the aetiology of GBM.  
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Material and Methods  
Neural Stem Cell Cultures 
Adult murine NSCs were derived from the SVZ by the protocol described in (Conti et al. 2005; 
Pollard et al. 2006). Transformed Ink4a/Arf-/-; EGFRvIII NSCs (IE-NSCs) were previously 
generated by the Maarten van Lohuizen laboratory (Netherlands Cancer Institute, NKI). NSCs 
were isolated from Ink4a/Arf-/- mice and transduced with EGFRvIII pMSCV retrovirus 
(Bruggeman et al. 2007).  
Co-culture assays 
40,000 cells per well were seeded in a 24-well plate either separately or as a 50:50 mix of WT 
and IE-NSCs. The proportion of each cell type was assessed by determining the percentage of 
GFP-positive cells by flow cytometry performed on an LSR-II Analyser (BD Biosciences).  
Differentiation of NSCs 
Sorting was performed by FACS at day five of the six-day assay for three biological repeats. 
Cells were seeded onto coverslips in NSC media for 24 hours following sorting. Media was 
then replaced for either NSC media with 10% FCS or NSC media without EGF addition. Media 
was replaced every other day and cells were fixed after 4 days in FCS or 6 days without EGF. 
Flow cytometry immunolabelling 
Cells were fixed in 2% formaldehyde and permeabilised in ice-cold 90% methanol. For BrdU 
analysis, cells were incubated with BrdU for 2 hours prior to fixation. Cells were then incubated 
with DNaseI prior to blocking. Primary antibodies (p-S6, cleaved-Caspase3 or BrdU, CST 
1:200) were detected with AlexFluor 546 secondary antibodies (Molecular Probes). Flow 
cytometry was performed on an LSR-II Analyser (BD Biosciences) and data analysed with the 
FlowJo software.  
RNA-sequencing analysis 
Sorting was performed by FACS at day 5 of the 6-day assay for 3 biological repeats. mRNA 
was isolated, fragmented, converted to cDNA and ligated to Illumina adapters. Sequencing was 
performed using the HiSeq 4000 system (Illumina). Differential expression was determined 
using the DESeq2 package (Love et al. 2014) and the resulting gene sets were analysed using 
IPA software (Qiagen)(Kramer et al. 2014). A ‘Core Analysis’ was performed for each 
comparison on genes differentially expressed with a false discovery rate of less than 10%.  
CRISPR gene targeting of NSCs  
gRNAs for targeting of Rbpj, Notch1, Notch2 and P53-/- were cloned into the pX330-U6-
Chimeric_BB-CBh-hSpCas9 (PX330) expression plasmid (gift from Feng Zhang, Addgene 
plasmid #42230)  as previously described (Ran et al. 2013). Details of Tsc2-/- NSC generation 
can be found in Supplemental Methods and gRNA sequences in Supplemental Table 2. NSCs 
were transfected with 2µg plasmid DNA and 0.125µg Puro-pPYCAGIP vector or linear 
hygromycin marker (Clontech 631625) by nucleofection (AMAXA 2B, Lonza). Selection was 
performed from 48 hours post-transfection until the emergence of resistant colonies. Pten-/- 
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NSCs were generated as described in (Bressan et al. 2017) and then transfected with gRNAs 
targeting P53 as described above. 
Quantification and Statistical Analysis 
Statistical analysis and data representation were performed using GraphPad Prism software. 
Statistical methods used and sample size (n) are indicated in the relevant figure legends. 
Adjusted p values are displayed as * p<0.05, ** p<0.01 and *** p<0.001. 
Data availability 
The raw data for the RNA-sequencing of wild-type and transformed NSCs have been deposited 
in the arrayexpress database under accession number E-MTAB-8580.  
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Figure Legends 
Figure 1. WT-NSCs show reduced proliferation in the presence of transformed NSCs. 
(A) Growth curves of WT and IE-NSCs cultured separately or (B) co-cultured over 6 days. 
N>10, ANOVA followed by Sidak’s multiple comparisons test. (C) Quantification of fold 
change in cell number relative to seeding density for each culture condition. N>10, ANOVA 
followed by Sidak’s multiple comparisons test. (D) Proportion of BrdU-positive cells in each 
culture condition at day 5 following a 2-hour BrdU chase. N=10, ANOVA followed by Sidak’s 
multiple comparisons test. (E) Representative immunoblot for phospho-histone-3 (p-H3) in 
WT-NSCs sorted at day 5 and quantification of p-H3 expression relative to β-actin. N=3, 
Student’s paired T test. (F) Fold change cell number of WT-NSCs cultured in co-cultures with 
varying proportions of IE-NSCs. N=3. 
Figure 2. WT-NSCs adopt a quiescent phenotype in the presence of transformed NSCs. 
(A) Top canonical pathways, (B) changes in cell cycle gene expression and (C) changes in 
quiescence and activation-associated gene expression in WT-NSCs in co-culture versus 
separate culture revealed by RNA-seq. N=3. (D) Immunofluorescence images and (E) 
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quantification of WT-NSCs stained with GFAP or BIII-Tubulin after being grown separately 
or in co-culture, then sorted and re-plated in differentiation inducing conditions. N=3, 2-way 
ANOVA followed by Sidak’s multiple comparisons test. (F) Growth curves and (G) proportion 
of BrdU-positive WT-NSCs after being grown separately or in co-culture and then sorted and 
re-plated. N=3. 
Figure 3. Quiescence of WT- NSCs is induced by direct contact with transformed NSCs 
and is associated with increased Notch activation 
(A) Flow cytometry plot showing p-S6 staining in WT and transformed NSCs in separate and 
co-culture and quantification of median fluorescence intensity. N=6, ANOVA followed by 
Sidak’s multiple comparisons test. (B) Growth curves of WT-NSCs cultured below transwell 
inserts with WT, transformed or mixed cultures. N=3. C Percentage of BrdU-positive WT-
NSCs from the inner ring of the three different cultures shown. N=3, one-way ANOVA 
followed by Tukey’s multiple comparisons test. (D) Heat map showing changes in Notch gene 
expression after RNA-seq and (E) after RT-qPCR in co-cultured transformed and WT-NSCs. 
N=3, 2-way ANOVA followed by Sidak’s multiple comparisons test. (F) Quantification of the 
fold change in NSC number after separate or co-culture with transformed cells (N=8) and (G) 
proportion of BrdU positive cells with and without addition of LY411575. N=4.  
Figure 4. Disruption of Notch signalling rescues WT- NSC proliferation in co-culture. 
(A, D, G) Western blot showing absence of RBPJ protein in Rbpj-/- clones (A), NOTCH1 
protein in Notch1-/- clones (D) and NOTCH2 protein in Notch2-/- clones (G). (B, E, H) Fold 
change cell number quantification and (C, F, I) proportion of BrdU-positive cells in EV and 
Rbpj-/- NSCs in separate and co-culture with transformed NSCs (B) N=4 (C) N=5; in EV and 
Notch1-/- NSCs in separate and co-culture with transformed NSCs (E) N=4 (F) N=5; and in EV 
and Notch2-/- NSCs in separate and co-culture with transformed NSCs (H) N=4 (I) N=5. 2-way 
ANOVA followed by Sidak’s multiple comparisons test.  
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Supplemental Tables 
Supplemental Table 1. Primers used in qPCR 
 
Target 
gene 
Forward primer Reverse primer 
Hes1 GGAAATGACTGTGAAGCACCTCC GAAGCGGGTCACCTCGTTCATG 
Hes5 GCCCGGGGTTCTATGATATT GAGTTCGGCCTTCACAAAAG 
Hes7 CATCAACCGCAGCCTAGAAGAG CACGGCGAACTCCAGTATCTCC 
Hey1 CCAACGACATCGTCCCAGGTTT CTGCTTCTCAAAGGCACTGGGT 
Hey2 TGAAGATGCTCCAGGCTACAGG CCTTCCACTGAGCTTAGGTACC 
Nrarp CAGACAGCACTACACCAGTCAG CCGAAAGCGGCGATGTGTAGC 
β-actin GGCACCACACCTTCTACAATG GGGGTGTTGAAGGTCTCAAAC 
 
Supplemental Table 2. gRNA sequences for deletion 
 
Target gene gRNA1 gRNA2 
Rbpj TGCAGTGGACGACGACGAGT  GTGGACGACGACGAGTCGGA  
Notch1 GGCGTTCAGTGCCTACACAA  
Notch2 GTCCACCTGCATTGACCGCG  AAGTGCATCGATCACCCGAA  
Tsc2 GAAGGCCGGCCTACCTCATT GCATGGCTCTTACAGGTACA 
 
 
Supplementary Figure Legends 
Supplemental Figure 1 
(A) Representative flow cytometry plot of BrdU staining in separately cultured NSCs at day 5. 
(B) Time-course of BrdU staining throughout the assay in separate culture. N=5, ANOVA 
followed by Sidak’s multiple comparisons test. (C) Fold change cell number quantification of 
NSCs cultured in the presence or absence of 50ng/ml BMP4. N=4, 2-way ANOVA followed 
by Sidak’s multiple comparisons test. (D) Western blot showing increased p-SMAD1/5/8 
expression in NSCs treated with 50ng/ml BMP4 for 24 hours relative to control NSCs (Con). 
(E) Representative flow cytometry plot of BrdU staining in co-cultured NSCs at day 5. (F) 
Time-course of BrdU staining throughout the assay in co-culture showing reduction in BrdU 
incorporation in WT-NSCs. N=5, ANOVA followed by Sidak’s multiple comparisons test. (G) 
Time-course of cleaved-caspase-3 expression showing increase in co-cultured WT NSCs. N=3, 
ANOVA followed by Sidak’s multiple comparisons test. 
Supplemental Figure 2 
(A) Changes in gene expression of classical marker genes in the ‘WT Mix vs WT Sep’ 
comparison. GFAP log2 fold change is off the scale at 5.4. (B) Comparison to published 
transcriptional analysis of quiescent and activated NSCs. Left - Transcription factors and co-
factors differentially expressed in quiescent and activated NSCs from (Morizur et al., 2018). 
Right – Heat map showing the expression of the genes identified by Morizur et al in the 
comparison of WT NSCs in separate (WT Sep) or co-culture (WT Mix). Genes enriched in 
quiescent NSCs were broadly upregulated in co-cultured WT NSCs, while those enriched in 
activated NSCs were broadly downregulated. (C) Immunofluorescence images and (D) 
quantification of WT-NSCs stained with Doublecortin after being grown separately or in co-
culture, then sorted and re-plated in differentiation inducing conditions. N=3, 2-way ANOVA 
followed by Sidak’s multiple comparisons test. 
Supplemental Figure 3 
(A) Western blot showing absence of TSC2 expression in Tsc2-/- clones. (B) Growth curves of 
transformed NSCs and Tsc2-/- or Cas9 control NSCs in separate or co-culture. Tsc2-/- clones 
grow more slowly than control and still show reduced growth in co-culture. N=4. (C) Fold 
change cell number quantification of growth curves. N=4, 2-way ANOVA followed by Sidak’s 
multiple comparisons test. (D) Expression of p-S6 in Cas9 and Tsc2-/- clones as determined by 
flow cytometry. mTOR activation is increased in Tsc2-/- NSCs. N=3. 
Supplemental Figure 4 
(A) Heat map of RNA-seq analysis showing changes in Notch ligand gene expression in IE-
NSCs. (B) RT-qPCR analysis of the Notch target genes, Hes1, Hes5 and Nrarp in WT NSCs 
treated with 2µM LY411575. Log2 fold change relative to control NSCs. N=3. (C) Growth 
curves of WT and transformed NSCs cultured in the standard assay with or without LY411575 
addition from day 3. (D) RT-qPCR analysis of the Notch target genes, Hes1, Hes5 and Nrarp 
in WT NSCs treated with 1µM crenigacestat. Log2 fold change relative to control NSCs. N=3. 
(E) Growth curves of WT and transformed NSCs cultured with or without crenigacestat 
addition from day 3. N=8, 2-way ANOVA followed by Sidak’s multiple comparisons test. (F) 
Proportion of BrdU positive cells following a 24-hour incubation with crenigacestat. N=4, 2-
way ANOVA with Sidak’s multiple comparisons test. The γ-secretase inhibitor crenigacestat 
also increases WT NSC proliferation in co-culture. 
Supplemental Figure 5 
(A, B, C and D) Growth curves of control EV NSCs (A),  Rbpj-/- NSCs (B), Notch1-/- NSCs 
(C), and Notch2-/- NSCs (D) cultured separately or in co-culture with transformed NSCs. N>4. 
(E) Western blot showing absence of RBPJ protein from Rbpj-/- transformed NSCs. (F) Fold 
change cell number of WT NSCs in separate or co-culture with EV or Rbpj-/- transformed 
NSCs. N=5, 2-way ANOVA followed by Sidak’s multiple comparisons test. (G) Proportion of 
BrdU-positive WT NSCs in separate or co-culture with EV or Rbpj-/- transformed cells. N=3, 
2-way ANOVA followed by Sidak’s multiple comparisons test. (H) Growth curves of 
transformed EV and Rbpj-/- clones cultured separately or in co-culture with WT NSCs. Both 
Rbpj-/- clones suppress the proliferation of WT NSCs to a comparable degree to the EV control 
transformed cells. 
Supplemental Figure 6 
(A) Growth curves of control EV NSCs and Pten-/-; P53-/- NSCs cultured separately or co-
cultured. N=3, ANOVA followed by Sidak’s multiple comparisons test. (B) Fold change cell 
number of WT NSCs in separate or co-culture with Pten-/-; P53-/- NSCs. N=3, ANOVA 
followed by Sidak’s multiple comparisons test. (C) Proportion of BrdU-positive WT NSCs in 
separate or co-culture with Pten-/-; P53-/- NSCs. N=3, two-way ANOVA followed by Sidak’s 
multiple comparisons test. 
 
 
Supplemental Methods 
Transwell and Fence assays 
For transwell assays, 140,000 NSCs were seeded on and below PLL-coated cell culture inserts 
(Merck Millipore). The growth of WT NSCs seeded below WT or IE-NSCs or a 50:50 mix 
was evaluated over 6 days. 
For Fence assays fences (Aix-Scientifics) were placed in each well of a PLL-coated 24-well 
plate. 100,000 NSCs were seeded in the inner ring and 400,000 in the outer ring. The fences 
were removed the following day and 10µM BrdU was added to the wells 48 hours after seeding 
for 2 hours. The fences were then replaced into the well and the cells in the inner ring were 
harvested and fixed in 2% formaldehyde. BrdU expression was analysed by flow cytometry as 
described below. 
Flow cytometry immunolabelling (extended details) 
Cells were fixed in 2% formaldehyde and permeabilised in ice-cold 90% methanol. Cells were 
incubated with the primary antibody (p-S6, cleaved-Caspase3 or BrdU, CST 1:200) for 1 hour. 
AlexaFluor 546 secondary antibodies (Molecular Probes) were used for detection. Controls 
with the primary antibody omitted were used to gate positive and negative cells. Flow 
cytometry was performed on an LSR-II Analyser (BD Biosciences) with FACS Diva software 
(BD Biosciences) and data were analysed using FlowJo software. For BrdU analysis, NSCs 
were incubated for two hours with 10µM BrdU prior to fixation. Before blocking, NSCs were 
then incubated for 45 minutes at 37°C in DNase I solution consisting of 20µl DNase I (Promega 
RQ1) in 250µl DNase buffer solution. The immunolabelling protocol was then followed as 
detailed above.  
Western blot analysis 
Cells were lysed directly in Laemmli buffer (50mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol 
in ddH2O) and heated at 95°C for 10 minutes. Protein quantification was carried out using a 
BCA Protein Assay kit (Pierce) according to the manufacturer’s instructions. 15-20μg 
denatured protein from each sample was run in XT sample buffer (BioRad) with 0.25% β-
mercaptoethanol on 10% SDS-PAGE Bis-Tris gels (pre-cast BioRad). Proteins were then 
blotted onto PVDF membranes (Thermo Fisher Scientific). Primary antibody incubation was 
overnight at 4oC in TBST with 5% BSA. All primary antibodies were from CST and were 
diluted 1:1000. Horseradish peroxidase-conjugated secondary antibodies (Abcam) diluted 
1:5000 were used for detection by the addition of an enhanced chemiluminescence (ECL) 
substrate (Promega). Western blot quantification was performed using Fiji software 
(Schindelin et al. 2012).  
Immunocytochemistry 
Cells were fixed in 4% PFA for 10 minutes and blocked for one hour in 5% goat serum and 
0.3% Triton. Primary antibodies (GFAP 1:300 Sigma, Beta-III-Tubulin 1:200 CST, DCX 
1:200 Abcam) were incubated overnight at 4°C and secondary antibodies (AlexaFluor 1:600 
ThermoFisher) were incubated with the coverslips for one hour. Coverslips were mounted with 
Vectashield (Vector Labs) and imaged on a ZEISS LSM-780 inverted confocal microscope. 
Image processing and quantification of pixel intensity was performed on FIJI. 
 
RNA Extraction and Quantitative RT-PCR 
RNA was extracted with the RNeasy mini kit (Qiagen) and SuperScript III reverse transcriptase 
(Thermo Fisher Scientific) was used for cDNA synthesis according to manufacturer’s 
instructions. RT-qPCR was performed using SYBR-Green Mastermix with ROX reference dye 
(Sigma).  A list of all primer sequences can be found in Supplementary Table 1. RT-qPCR was 
performed on an ABI 7900HT Fast Real Time PCR machine (Applied Biosystems) and 
analysed on SDS Biosystem software. Relative gene expression was calculated using the ΔΔCt 
method normalised to β-actin expression (Livak and Schmittgen 2001). 
RNA-sequencing analysis (extended details) 
Sorting was performed by FACS at day 5 of the 6-day assay for 3 biological repeats. Cells were 
lysed and RNA extracted with the RNeasy mini kit (Qiagen). RNA samples were quantified 
using a Qubit fluorometer (Thermo Fisher Scientific) and the quality assessed by TapeStation 
electrophoresis (Agilent). mRNA was isolated using oligo dT beads. mRNA was then 
fragmented, converted to cDNA and ligated to Illumina adapters. Following sample indexing, 
the quality of cDNA libraries was also assessed by TapeStation. Sequencing was performed 
using the HiSeq 4000 system (Illumina). Sequencing reads were aligned using TopHat2 (Kim 
et al. 2013) and differential expression was analysed using the DESeq2 package (Love et al. 
2014). The resulting gene sets were analysed using Ingenuity Pathway Analysis (IPA) software 
(Qiagen)(Kramer et al. 2014). A ‘Core Analysis’ was performed for each comparison on genes 
differentially expressed with a false discovery rate (FDR) of less than 10%.  
CRISPR gene targeting of NSCs (extended details) 
gRNAs for targeting of Rbpj, Notch1, Notch2 and P53-/- were cloned into the pX330-U6-
Chimeric_BB-CBh-hSpCas9 (PX330) expression plasmid (gift from Feng Zhang, Addgene 
plasmid #42230)  as previously described (Ran et al. 2013). gRNAs for targeting Tsc2 were 
cloned into gRNA expression plasmids (gift from George Church, Addgene plasmid #41824) 
(Mali et al. 2013). These were then co-transfected with an hCas9 plasmid (gift from George 
Church, Addgene plasmid #41815). gRNA sequences can be found in Supplemental Table 2. 
NSCs were transfected with plasmids by nucleofection (AMAXA 2B, Lonza) using 
programme A-033. 2-3x106 cells were resuspended in 100µl mouse neural stem cell 
nucleofector buffer (Lonza) with 2µg plasmid DNA. NSCs were either transfected with 2ug 
PX330 vector containing gRNAs targeted to Rbpj, Notch1, Notch2 and P53 or 0.6µg each of 
hCas9 and the two gRNA expression plasmids containing the Tsc2-targeting gRNAs. NSCs 
were also co-transfected with 0.125ug of Puro-pPyCAGIP vector or linear hygromycin marker 
(Clontech 631625) for selection. Empty vector or Cas9 only controls were also performed. 
Cells were recovered post-transfection with pre-warmed NSC growth media into a 10cm2 dish. 
Selection with 0.25ug/ml puromycin or 250ug/ml hygromycin was performed from 48 hours 
post-transfection until the emergence of resistant colonies. These were then picked manually 
with a p20 pipette and transferred to a 48 well plate for expansion and analysis. Pten-/- NSCs 
were generated as described in (Bressan et al. 2017) and then transfected with gRNAs targeting 
P53 as described above. 
Quantification and Statistical Analysis 
Statistical analysis and data representation were performed using GraphPad Prism software. 
Statistical methods used are indicated in the relevant figure legends. The sample size (n) is 
described in the figure legends and refers to the number of independent replicate experiments 
performed. Adjusted p values are displayed as * p<0.05, ** p<0.01 and *** p<0.001. 
Data availability 
The raw data for the RNA-sequencing of wild-type and transformed NSCs have been deposited 
in the arrayexpress database under accession number E-MTAB-8580.  
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